Breast Cancer

Here are 5 presentations that oncology APPs should know about, from patient management to practice management.

The FDA has approved a biosimilar of pertuzumab that is indicated for multiple breast cancer settings.

Kristi Orbaugh, MSN, RNP, AOCN, AOCNP, shared the key toxicities of each CDK4/6 inhibitor and how to monitor for them.

T-DXd plus pertuzumab improved PFS and DOR across HER2+ breast cancer subgroups, regardless of prior therapy or PIK3CA mutation status.

Dermatitis and lymphedema are among the most pertinent adverse effects of radiation to the breast, according to Alexa M. Lantz, MSPAS, PA-C.

La-Urshalar Brock, FNP-BC, CNM, describes tactics for managing dermatologic AEs in patients with breast cancer as part of a multidisciplinary care team.

Kevin Y. Chen, PharmD, MS, BCOP, CPP, discusses how next-generation sequencing improves biomarker testing and treatment planning in solid tumors.

A patient with breast cancer and generalized anxiety disorder was able to avoid an unnecessary mastectomy with virtual reality, said Kelly Preti, DNP.

T-DXd plus pertuzumab improved progression-free survival vs THP regardless of prior therapy, hormone receptor status, or PIK3CA mutations.

The combination of sacituzumab with pembrolizumab did not lead to a decline in physical functioning or quality of life in patients with metastatic TNBC.

The DESTINY-Breast11 trial found neoadjuvant T-DXd followed by THP improved pathologic complete response vs ddAC-THP in high-risk, HER2-positive early breast cancer.

Long-term NATALEE data show adjuvant ribociclib plus an aromatase inhibitor (AI) improves invasive disease–free survival vs AI alone in HR+, HER2– early breast cancer.

Following imlunestrant’s approval, Komal Jhaveri, MD, FACP, compares the oral SERD to its counterpart, elacestrant, in terms of composition and trials.

A network to connect patients with unused medications with patients in need brought $18 million of free cancer medication while reducing drug waste.

Courtney Moore, APRN, FNP-C, OCN, discusses planning beyond first-line CDK4/6 inhibitors and supportive care strategies for patients with HR+/HER2– disease.

The FDA has approved imlunestrant for the treatment of patients with ESR1-mutated ER+, HER2- metastatic breast cancer.

Subcutaneous pembrolizumab has been approved across all indications, cutting chair and administration times with a median injection time of 2 minutes.

Courtney Moore, APRN, FNP-C, OCN, discusses how patient comorbidities and adverse effect profiles guide CDK4/6 inhibitor choice in the first-line setting.

Expert Kelsey Martin shares nursing insights on balancing glucose control and GI side effects when caring for patients on PI3K and AKT inhibitors.

Familiarity with each component of antibody-drug conjugates helps nurses and APPs deliver proactive adverse event management to patients with cancer.

Catering supportive care to the individual being treated helps better meet the needs of each patient, says Michelle Kirschner, MSN, RN, ACNP, APRN-BC.

Experts share advice on tailoring frontline treatment and managing toxicities for individuals with hormone receptor–positive metastatic breast cancer.

Nurse practitioners give their advice on making treatment choices based on the patient’s medical history and preferences.

Paolo Tarantino, MD, PhD, discusses ADC structure, toxicity, and nursing consideration for the treatment of patients with breast cancer.

Oncology nurses play a key role in monitoring, managing, and personalizing CDK4/6 inhibitor treatment to minimize toxicities and protect quality of life, according to Courtney Moore, APRN, FNP-C, OCN.